Skip to main content
OpenTrials
Completed

NCT Number: NCT02457156

Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy

The purpose of this study is to compare two different techniques of performing a pancreatic anastomosis; Cattell-Warren versus Blumgart to determine if a Blumgart anastomosis reduces pancreatic remnant leak, post-operative complications and overall length of hospital stay.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Royal Liverpool University Hospital

Liverpool, Merseyside, L7 8XP, United Kingdom

About this study

This is a randomised controlled, phase III, double blinded, multicentre clinical trial comparing Cattell-Warren (CWA) versus. Blumgart (BA) methods of pancreaticojejunostomy following pancreaticduodenectomy for supected malignancy of the pancreatic head.

The primary objective of the trial is to establish if the Blumgart anastomosis reduces pancreatic remnant leak and in turn complications, hospital stay, cost and promote enhanced recorvery programs.

506 patients (253 patients per treatment arm) will be recruited from approximately 7 centres throughout the United Kingdom.

Patients recommended for resection who provide written informed consent will be randomised to one of the following treatment arms on the day of surgery by the surgeon:

Arm A: Blumgart method of panreaticojejunostomy. Arm B: CattellWarren method pf pancreaticojejunostomy.

Randomisation will be undertaken intra-operatively, following pancreatic head excision, just prior to pancreatic head remnant reconstruction.

Patients will be assessed post operatively on days 3 to 7 and on day of dishcharge from hospital. Patients will continue to be followed up in the outpatient setting at 3, 6 and 12 months post surgery.

All laboratory and physical assessments performed will be in line standard care.

Blood samples for the translational study will be taken subject to informed consent pre-operatively and post-operatively 5 days after surgery.

A histological (H&E stained) slide of the pancreatic transection margin should be taken as routine. This will be requested from each patient for central pathology review to assess the amount of fibrosis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients undergoing an elective pancreato-duodenectomy for presumed malignancy.
  • Ability of the subject to understand the nature and consequences of the trial.
  • Ability to rovide writen informed consent.
  • Age 18 or greater.

Exclusion criteria

  • Patients undergoing extended pancreato-duodenectomy
  • Left, central or total pancreatectomy.
  • Arterial resection or multi-visceral resection
  • Previous pancreatic surgery
  • Surgery for known chronic pancreatitis.
  • Recruited to any other pancreatic resection trial.
  • Pregnant women.
  • Women of childbearing potential, including women whose last menstrual period was less than one year prior to screening, unable or unwilling to use adequate contraception from time of consent up to the day of surgery.

Treatment and study plan

Blumgart Anastomosis

Procedure
  • Trans pancreatic suture "U" stich incorporating pancreatic parenchyma and jejunal serosa, left loose.
  • Pancreatic duct to jejunal mucosa sutures, inserted and tied.
  • Trans pancreatic suture "U" stich brought back through the jejuanl serosa anteriorly, tied.

Other names: Pancreatico-jejunostomy

Cattell-Warren Anastomosis

Procedure
  • Posterior row of sutures from pancreatic parenchyma to jejunal serosa, inserted and tied.
  • Pancreatic duct to jejunal mucosa sutures, inserted and tied.
  • Anterior row of sutures from pancreatic parenchyma to jejunal serosa, inserted and tied.

Other names: Pancreatico-jejunostomy

Octreotide

Drug

Octrotide (100ug) to be administered on the evening before surgery and then 100ug three times daily on the day of surgery and post operative days 1 - 6.

Other names: Sandostatin

Primary outcomes

  1. Presence or absence of post-operative pancreatic fistula

    Time frame: Assessed up to 3 months after surgery.

    Post-operative pancreatic fistula are defined as any abnormal connection between the pancreatic duct epithelium and another epithelised surface, which contains pancreatic derived, enzyme rich fluid. This will be assessed up to 3 months following surgery on inpatient days 3-7, day of discharge (expected to be 1 - 5 weeks after surgery) and 3 month follow up.

Secondary outcomes

  1. Entry into programs of adjuvent therapy

    Time frame: 3, 6 and 12 month follow up

  2. Mortality Rate

    Time frame: Death due to any cause during the study will be recorded

  3. Rate of delayed gastric emptying

    Time frame: Post operative day 3, 5, 7, and the day of discharge, which is expected to be between 1 - 5 weeks after surgery.

  4. Rate of wound infections

    Time frame: Post operative day 3, 5, 7, the day of discharge, which is expected to be between 1 - 5 weeks after surgery and 3, 6 and 12 month follow up

  5. Rate of pulmonary infection

    Time frame: The day of discharge, which is expected to be between 1 - 5 weeks after surgery and 3 month follow up.

  6. Rate of post-operative fluid collections

    Time frame: post operative days 3-7, the day of discharge, which is expected to be between 1 - 5 weeks after surgery and 3 month follow-up

  7. Operation time

    Time frame: Day of surgery

  8. Rate of intra and post-operative bleeding

    Time frame: day of surgery, post operaive day 3, 5, 7 and the day of discharge, which is expected to be between 1 - 5 weeks after surgery

  9. Rate of re-operation

    Time frame: Up to 12 months after surgery

  10. Rate of venous thrombo-embolism

    Time frame: Post operative day 3, 5, 7, the day of discharge, which is expected to be between 1 - 5 weeks after surgery, 3, 6 and 12 month follow up

  11. Length of hospital stay

    Time frame: The day of discharge, which is expected to be between 1 - 5 weeks after surgery, 3, 6 and 12 month follow-up

  12. Quality of Life measured by the QLQ-C30 questionnaire

    Time frame: Enrolment, the day of discharge, which is expected to be between 1 - 5 weeks after surgery, 3, 6 and 12 month follow-up

  13. Health economic evaluation measured by the EQ-5D questionnaire

    Time frame: Enrolment, the day of discharge, which is expected to be between 1 - 5 weeks after surgery, 3, 6 and 12 month follow-up

Sponsors and collaborators

Lead sponsor

University of Liverpool

Other

Collaborators

  • Cancer Research UK

Registry information

Official study title

PANasta Trial Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy - a Double Blinded Multi Centred Trial

Acronym: PANasta

Important dates

Study start
2015
Primary completion
2018
Study completion
2019
First posted
May 29, 2015
Registry last updated
Mar 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.